{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:09:06Z","timestamp":1788948546404,"version":"build-2803163510"},"reference-count":23,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Doxazosin, a selective \u03b11-receptor antagonist, is widely used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, its cardiovascular effects remain clinically relevant, particularly in older patients. This systematic review and meta-analysis evaluated blood pressure, heart rate, headache and vertigo during doxazosin treatment. PubMed\/MEDLINE, the Cochrane Library, CNKI, Wanfang Data, Google Scholar and ScienceDirect were searched using Chinese and English terms related to doxazosin, BPH, prostate and cardiovascular outcomes. Sixteen evidence reports were included: 12 primary studies, 2 pooled analyses and 2 secondary review sources that supplied aggregate trial data. The pooled analyses showed no statistically significant difference in systolic blood pressure (MD 1.44, 95% CI \u22124.17 to 7.06; p=0.61), diastolic blood pressure (MD \u22120.33, 95% CI \u22123.68 to 3.03; p=0.85), headache (OR 0.99, 95% CI 0.73\u20131.34; p=0.95) or heart rate (MD 0.98, 95% CI \u22120.89 to 2.84; p=0.30). Vertigo was more frequent with doxazosin than with control treatment (OR 1.93, 95% CI 1.50\u20132.49; p&lt;0.00001). Risk-of-bias assessment identified 2 reports at low risk, 10 with some concerns, 1 at high risk, 1 observational study of moderate quality, and 2 secondary reviews for which Cochrane Risk of Bias 2 and the Newcastle\u2013 Ottawa Scale were not applicable. Doxazosin was not associated with statistically significant average changes in blood pressure or heart rate, but the increased occurrence of vertigo warrants counselling and monitoring, particularly in older patients at risk of falls.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-cardiovascular-effects-of-doxazosin-in-the-treatment-of-prostatic-hyperplasia<\/jats:p>","DOI":"10.7573\/dic.2026-4-12","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:36:56Z","timestamp":1788946616000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular effects of doxazosin in the treatment of prostatic hyperplasia"],"prefix":"10.7573","author":[{"given":"Qianhui","family":"Fan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04eymdx19","id-type":"ROR","asserted-by":"publisher"}],"name":"Hebei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Fan","sequence":"additional","affiliation":[{"name":"Hebei Armed Police Corps Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihang","family":"Kuang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00j5y7k81","id-type":"ROR","asserted-by":"publisher"}],"name":"Longgang Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafu","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041kmwe10","id-type":"ROR","asserted-by":"publisher"}],"name":"Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tGratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099\u20131109. https:\/\/doi.org\/10.1016\/ j.eururo.2014.12.038","DOI":"10.1016\/j.eururo.2014.12.038"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tSchwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193\u2013199. https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01956.x","DOI":"10.1111\/j.1442-2042.2007.01956.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tKaplan SA. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int. 2008;102(Suppl. 2):3\u20137. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08086.x","DOI":"10.1111\/j.1464-410X.2008.08086.x"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tJanknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol. 1993;24:319\u2013326. https:\/\/doi.org\/ 10.1159\/000474321","DOI":"10.1159\/000474321"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tFawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154:105\u2013109.","DOI":"10.1016\/S0022-5347(01)67240-9"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tLund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl. 2003;1:5\u201313. https:\/\/doi.org\/10.1080\/ 08038020310000078","DOI":"10.1080\/08038020310000078"},{"key":"ref6","unstructured":"7.\tMathur RP, Nayak S, Sivaramakrishnan R, Jain V. Role of alpha blockers in hypertension with benign prostatic hyperplasia. J Assoc Physicians India. 2014(Suppl. 9);62:40\u201344."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tWolak T, Toledano R, Novack V, Sharon A, Shalev A, Wolak A. Doxazosin to treat hypertension: it\u2019s time to take it personally \u2014 a retrospective analysis of 19, 495 patients. J Hypertens. 2014;32:1132\u20131137; discussion 1137. https:\/\/doi.org\/ 10.1097\/HJH.0000000000000119","DOI":"10.1097\/HJH.0000000000000119"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tLepor H, Kazzazi A, Djavan B. \u03b1-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol. 2012;22:7\u201315. https:\/\/doi.org\/10.1097\/MOU.0b013e32834d9bfd","DOI":"10.1097\/MOU.0b013e32834d9bfd"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tKim TN, Nam JK, Lee KS, et al. Reasons for prescription change of \u03b11-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2014;84:427\u2013432. https:\/\/doi.org\/10.1016\/ j.urology.2014.02.068","DOI":"10.1016\/j.urology.2014.02.068"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tKirby RS, Chapple CR, Sethia K, Flannigan M, Milroy EJ, Abrams P. Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety. Prostate Cancer Prostatic Dis. 1998;1:163\u2013171. https:\/\/doi.org\/ 10.1038\/sj.pcan.4500220","DOI":"10.1038\/sj.pcan.4500220"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tPompeo AC, Rosenblatt C, Bertero E, et al. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract. 2006;60:1172\u20131177. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01107.x","DOI":"10.1111\/j.1742-1241.2006.01107.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tRoehrborn CG, Prajsner A, Kirby R, Andersen M, Quinn S, Mallen S. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. Eur Urol. 2005;48:445\u2013452; discussion 452. https:\/\/doi.org\/10.1016\/j.eururo.2005.05.010","DOI":"10.1016\/j.eururo.2005.05.010"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tRoehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology. 1996;48:406\u2013415. https:\/\/doi.org\/10.1016\/S0090- 4295(96)00208-7","DOI":"10.1016\/S0090-4295(96)00208-7"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tRahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 2006;13:1405\u20131409. https:\/\/doi.org\/10.1111\/j.1442-2042.2006.01590.x","DOI":"10.1111\/j.1442-2042.2006.01590.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tChristensen MM, Bendix Holme J, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol. 1993;27:39\u201344. https:\/\/doi.org\/10.3109\/ 00365599309180412","DOI":"10.3109\/00365599309180412"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tHooper PL. Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins. Curr Control Trials Cardiovasc Med. 2001;2:251\u2013253. https:\/\/doi.org\/10.1186\/cvm-2-6-251","DOI":"10.1186\/cvm-2-6-251"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tNickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62:1547\u20131559. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01880.x","DOI":"10.1111\/j.1742-1241.2008.01880.x"},{"key":"ref18","unstructured":"19.\tZhang Q, Wang R. Cardiovascular safety of doxazosin in hospitalized patients with benign prostatic hyperplasia. Pract Pharm Clin Rem. 2018;21:171\u2013174. https:\/\/doi.org\/10.14053\/j.cnki.ppcr.201802012"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tZusman R. Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia. Clin Cardiol. 2004;27:63\u201369. https:\/\/doi.org\/10.1002\/clc.4960270203","DOI":"10.1002\/clc.4960270203"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tGillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. 1995. 154(1), 110\u2013115. https:\/\/doi.org\/10.1016\/S0022-5347(01)67243-4","DOI":"10.1016\/S0022-5347(01)67243-4"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tChung MS, Lee SH, Park KK, Yoo SJ, Chung BH. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. Int J Clin Pract. 2011;65:1193\u20131199. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02759.x","DOI":"10.1111\/j.1742-1241.2011.02759.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tKirby RS, Quinn S, Mallen S, Jensen D. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract. 2004;58:6\u201310 https:\/\/doi.org\/10.1111\/j.1368-5031.2004.0031.x","DOI":"10.1111\/j.1368-5031.2004.0031.x"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/09\/dic.2026-4-12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:37:07Z","timestamp":1788946627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/cardiovascular-effects-of-doxazosin-in-the-treatment-of-prostatic-hyperplasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-12","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"dic.2026-4-12"}}